-
Company Insights
Innovation and Patenting activity of Shilpa Medicare Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Shilpa Medicare Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Chemotherapy Induced Anemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Chemotherapy Induced Anemia - Drugs In Development, 2023’, provides an overview of the Chemotherapy Induced Anemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Polyarticular Juvenile Idiopathic Arthritis (PJIA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Drugs In Development, 2023’, provides an overview of the Polyarticular Juvenile Idiopathic Arthritis (PJIA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polyarticular Juvenile Idiopathic Arthritis (PJIA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Drugs In Development, 2023’, provides an overview of the Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Juvenile Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Juvenile Arthritis - Drugs In Development, 2023’, provides an overview of the Juvenile Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Ovarian Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Ovarian Disease - Drugs In Development, 2023’, provides an overview of the Ovarian Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ovarian Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Psoriatic Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psoriatic Arthritis - Drugs In Development, 2023’, provides an overview of the Psoriatic Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Axial Spondyloarthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Axial Spondyloarthritis - Drugs In Development, 2023’, provides an overview of the Axial Spondyloarthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Ankylosing Spondylitis (Bekhterev’s Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2023’, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...